Ipsen To Acquire Memo Therapeutics For Over 700 Mln Euros, Expanding Rare Disease Portfolio

Ipsen agreed to acquire Memo Therapeutics AG in a definitive deal worth approximately €700M. The transaction is a meaningful strategic step for Ipsen in biopharma, with likely implications for its pipeline and near-term valuation of the acquirer. Overall tone is mildly positive given the size of the purchase and definitive nature of the agreement.

Analysis

Ipsen agreed to acquire Memo Therapeutics AG in a definitive deal worth approximately €700M. The transaction is a meaningful strategic step for Ipsen in biopharma, with likely implications for its pipeline and near-term valuation of the acquirer. Overall tone is mildly positive given the size of the purchase and definitive nature of the agreement.